Is There A Drug To Stop Gambling

  

Last updated: 10/25/2018
Author: Addictions.com Medical Review

  1. Is There A Drug To Stop Gambling Control
  2. Stop Gambling Addiction
  3. Is There A Drug To Stop Gambling Laws
  4. Is There A Drug To Stop Gambling
  • There is another perspective, though. I almost fell off my chair when I accidentally came across information that ropinirole could trigger impulsive gambling. I have been taking this drug for eight years for restless legs. I can’t stop gambling and I never gambled in my life I’m also so scared u want to stop taking my primopexole.
  • Mar 01, 2017  I’m Addicted to Gambling – Why It’s So Hard to Stop Gambling addiction can be split into two categories: problem gambling and pathological gambling. 1% of the United States population are pathological gamblers while an additional 2-3% are problem gamblers.
  • Parkinson's Drugs May Lead to Compulsive Gambling, Shopping, and Sex. “That is a striking psychological side effect rate,” said study author Thomas Moore, a drug safety researcher at the Institute for Safe Medication Practices. “There are a lot of forms of impulse control, but this is a striking and unusual list” of behaviors.
  • Gambling addiction is one of the hardest problems to stop. It can be an all-consuming behavior that can result in some very bad consequences. Here are ten ways to stop gambling forever.

For customers accessing the services from Great Britain (“GB”) MT SecureTrade Limited is licensed and regulated by the Gambling Commission and holds a Remote is there a drug to stop gambling Casino Operating License number 39575. The fact is, gambling addicts cannot 'just stop' any more than an alcoholic or drug addict can stop using their drug of choice. Gambling addiction causes changes in the gambler's brain in ways that require treatment and recovery to arrest the addiction.

Reading Time: 3minutes

If you are wondering how to stop gambling addiction you have taken the first step on the road to recovery.

Gambling is everywhere, it is on the internet, it is at every gas station, and it is on the roads at casinos and race tracks. A gambling addiction can be a hard habit for you to get rid of, but there are resources out there that focus specifically on gambling addicts and can help you overcome your addiction.

Why Compulsive Gambling is a Problem

Gambling may start out innocent but after a few wins or loses you may have begun to form a habit. The rush you get from gambling may cloud your judgment and cause you to bet money that you do not have.

Is There A Drug To Stop Gambling Control

A gambling addiction can be a hard addiction to overcome alone.

According to www.gamblinghelp.org, compulsive gambling often starts quietly and results in your need to continue betting in hopes of breaking even. Ultimately, desperation will set in and the eventual destruction of your personal life, family relationships, and career can occur.

Compulsive gamblers often feel depressed and guilty when they lose a lot of money and this depression and guilt can cause many gamblers to have suicidal thoughts.

This is why it is important for you to get help of you have a gambling problem.

Finding Help

If you have admitted to yourself that you have a problem and that you need to find a way to stop your gambling addiction, you have completed the first step in helping yourself overcome your addiction.

Now that you have the willpower to stop you will most likely need help from outside sources to help you complete your goal. There are gambling hotlines out there that you can call and that can provide you with advice and support with battling your gambling problem. Gambling hotlines can also provide you with referrals to gambling addiction programs and rehabilitation centers that may be a smart choice for you to involve yourself with.

Gambling is a highly psychological addiction that will take time and effort for you to overcome the addiction. Attending a gambling rehab will provide you with the support, education, and resources for you to get over your addiction. Gambling rehabs have trained staff that will be available for you to talk to as well as other people who are overcoming their addictions with you. At a gambling rehab you will have people available to talk to 24/7 and who understand what you are going through without passing judgment on you.

How to make money gambling on soccer. That’s where the vigorish will get you.

If you do not want to go to a rehab program you can always find a gambling anonymous group that you can attend on a weekly basis and this will also provide you with encouragement and support in overcoming your addiction. The answer on how to stop gambling addiction will vary from each person, but once you decide that you want to stop your addiction know that there are resources out there to help you achieve your goal and you can find many of them via the internet or by contacting a gambling help line.

Minn Med. Author manuscript; available in PMC 2007 Apr 26.
Published in final edited form as:
NIHMSID: NIHMS18960
See other articles in PMC that cite the published article.

Abstract

Pathological gambling has received little attention from clinicians and researchers despite prevalence rates similar to or greater than those of schizophrenia and bipolar disorder. This article summarizes the phenomenology and associated psychopathology of this public health problem and presents results of studies of 3 types of pharmacological agents used to treat this disorder: serotonin reuptake inhibitors, opioid antagonists, and mood stabilizers.

Pathological gambling is characterized by persistent and recurrent gambling and is associated with impaired functioning, reduced quality of life, and high rates of bankruptcy, divorce, and criminal activity. The problem usually begins during adolescence or early adulthood, with males tending to start at an earlier age., Although gambling among women has become a significant problem with the proliferation of lottery tickets, casinos, and Internet gambling sites and the gradual acceptance of gambling as a legitimate form of entertainment, epidemiological studies still suggest that men represent the majority of pathological gamblers and that being male appears to be a risk factor for developing a gambling addiction during adolescence., Although there have been few prospective studies on the subject, there is a high incidence of pathological gambling among adolescents and young adults and a lower incidence among older adults; in addition, periods of abstinence and relapse are common among all pathological gamblers.

Diagnosing Pathological Gambling

Studies have shown that pathological gambling usually goes unrecognized in clinical settings mainly because clinicians fail to screen for the behavior. However, diagnosing the problem is usually straightforward and can be done by asking patients if they feel they cannot control their gambling or if they are preoccupied with gambling. An affirmative answer can be followed up with questions determining the degree of impairment (whether it’s affecting patients’ social or family life, their financial well-being, or their work) and the distress that this behavior causes. It must also be determined that a patient’s gambling behavior is not simply a symptom of bipolar disorder. Simple self-reporting and clinician-administered screening and diagnostic measures for pathological gambling and bipolar disorder are available.7

Relationship to Other Mental Illnesses

Although pathological gambling is classified as an impulse-control disorder, it has many similarities to substance abuse. Clinical similarities are reflected in the diagnostic criteria for both disorders and include symptoms of tolerance and withdrawal; repeated, unsuccessful attempts to cut back or stop; and impairment in major areas of life functioning. Epidemiological data also support a relationship between pathological gambling and substance abuse, as pathological gamblers are also likely to abuse alcohol and other drugs. Phenomenological data further support a relationship between behavioral and drug addictions. For example, high rates of pathological gambling and substance abuse have been reported during adolescence and young adulthood. In addition, the telescoping phenomenon, which reflects the rapid rate of progression from initial to problematic behavior in women compared with men, initially described for alcoholism has been applied to pathological gambling. Emerging biological data, such as those identifying genetic contributions to alcohol use and gambling disorders and changes in brain activity underlying gambling urges and cocaine cravings, provide further support for a relationship between pathological gambling and substance abuse.,

Although much data support a close relationship between pathological gambling and substance abuse, pathological gambling also has been categorized as an obsessive-compulsive spectrum disorder as well as an affective spectrum disorder. The inclusion of pathological gambling within the obsessive-compulsive spectrum is based on the fact that people who are compulsive gamblers tend to have repetitive thoughts and behaviors. Although ritualistic behaviors are common among people with obsessive-compulsive disorder (OCD) and pathological gambling, other aspects of the conditions are different. For example, gambling has an ego-syntonic nature, meaning it is acceptable to or consistent with a person’s fundamental beliefs and personality, while the nature of compulsions in OCD are ego-dystonic or inconsistent with one’s beliefs. Biological differences also exist, including increased activity in the cortico-basal ganglionic-thalamic circuitry described during symptom-provocation studies of OCD and decreased activity in these regions of the brains of pathological gamblers, and the activation of the reward circuit observed in cue elicitation studies of pathological gamblers.,

The association of pathological gambling with mood disorders has led to suggestions that it is an affective spectrum disorder. Many people who are pathological gamblers report that the pleasurable yet problematic behaviors alleviate negative emotional states. Because the behaviors are risky and self-destructive, the question has also been raised as to whether pathological gambling reflects subclinical mania or cyclothymia. Depression in individuals who are pathological gamblers may be distinct from primary or uncomplicated depression. That is, depression in people who are pathological gamblers may represent a response to financial difficulties, shame, and embarrassment. In addition, rates of co-occurrence of pathological gambling and bipolar disorder may not be as high as initially thought. Nonetheless, in some individuals who are pathological gamblers, brain-imaging studies have found regional differences in brain activity distinguishing bipolar subjects from controls and subjects who are pathological gamblers from controls when asked to perform a cognitive task involving attention and response inhibition.

Pharmacological Treatment of Pathological Gambling

Several medications have been studied as treatments for pathological gambling, and the range of medication classes—opioid antagonists, serotonin reuptake inhibitors (SRIs), mood stabilizers—that have been tested reflects the different ways pathological gambling is categorized (Table 1). Because no medication currently is approved by the Food and Drug Administration for treating pathological gambling, patients should be informed of off-label use of medications for pathological gambling, as well as the empirical basis for considering medication as a treatment.

Table 1

Pharmacotherapy Trials for Pathological Gambling-Double-Blind Trials

MedicationSubjectsMean Daily DoseOutcome
Fluvoxamine(Luvox)115 enrolled
10 completed
195 mgFluvoxamine superior to placebo
Naltrexone (ReVia)289 enrolled
45 completed
188 mgNaltrexone group significantly improved compared with placebo
Fluvoxamine(Luvox)332 enrolled
13 completed
200 mgFluvoxamine not statistically significant from placebo
Paroxetine (Paxil)453 enrolled
41completed
51.7 mgParoxetine group significantly improved compared to placebo
Paroxetine (Paxil)576 enrolled
45 completed
50 mgParoxetine and placebo groups with comparable improvement
Lithium carbonate SR (Lithobid SR)640 Bipolar-spectrum subject enrolled
29 completed
1,170 mgLithium group significantly improved compared with placebo
Sertraline (Zoloft)760 enrolled
44 completed
95 mgSimilar improvement in both groups
Nalmefene8207 enrolled
73 completed
25mg, 50mg or 100mgNalmefene group significantly improved compared to placebo
1Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Carrwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biol Psychiatry. 2000;47(9):813-7
2Kim SW, Grant JF, Adson DE, Shin YC. Double-blind naltrenone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49(11):914-21
3Blanco C, Petkova E, Ibanez A, Saiz-Ruiz J. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14(1):9-15
4Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli RM. A double-blind placebo controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002;63(6):501-7
5Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-center randomized controlled trial. Int Clin Psychopharmacol. 2003;18(4):243-9
6Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and effective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162(1):137-45
7Saiz-Ruiz J, Blanco C, Ibanez A, Masramon X, Gomez MM, Madrigal M, Diez T. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry. 2005;66(1):28-33
8Grant JE, Potenza MN, Hollander E, et al. A multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163(12):303-12

Opioid Antagonists

Pathological gambling and substance abuse have the following characteristics in common: 1) repetitive or compulsive engagement in a behavior despite adverse consequences, 2) diminished control over the problematic behavior, 3) an urge or craving prior to engagement in the behavior, and 4) a hedonic thrill when taking part in the behavior. These features have led to a description of pathological gambling as a behavioral addiction.

Dopaminergic systems that influence the rewarding and reinforcing behaviors involved in substance abuse also have been implicated in pathological gambling. Alterations in dopaminergic pathways have been suggested as the underlying cause of reward-seeking behaviors such as gambling and drug use. Gambling or using drugs then triggers the release of dopamine, which produces feelings of pleasure. Opioid receptor antagonists inhibit dopamine release in the nucleus accumbens and ventral pallidum through the disinhibition of gamma-aminobutyric acid (GABA) input to the dopamine neurons in the ventral tegmental area. Opioid antagonists are thought to decrease dopamine neurotransmission in the nucleus accumbens and the motivational neurocircuitry, thus dampening gambling-related excitement and cravings.

Given their ability to modulate dopaminergic transmission in the mesolimbic pathway, opioid-receptor antagonists have been tested as a possible treatment for pathological gambling. Initially, open-label treatment suggested the efficacy of naltrexone, an FDA-approved treatment for alcohol and opioid dependence, in reducing the intensity of urges to gamble, thoughts about gambling, and the behavior itself when given in high doses (range: 50 to 250mg/d; mean dose: 157 mg/d).

A 12-week double-blind placebo-controlled trial of naltrexone demonstrated superiority to placebo in 45 subjects who were pathological gamblers. Naltrexone (mean dose: 188mg/d) was effective in reducing the frequency and intensity of gambling urges, as well the behavior itself. A separate analysis showed that naltrexone was more effective in gamblers with more severe urges than in those who described their urges to gamble as moderate. Naltrexone’s clinical use, however, is limited by its side effects such as nausea as well as its tendency to elevate liver enzymes, especially in patients taking nonsteroidal anti-inflammatory drugs.

A recently completed multi-center study further demonstrated the efficacy of another opioid antagonist, nalmefene, in the treatment of pathological gambling. In a sample of 207 subjects, nalmefene demonstrated statistically significant improvement in gambling symptoms compared with a placebo in a 16-week double-blind trial. Although nalmefene, like naltrexone, causes nausea in some individuals, it was not associated with hepatotoxicity. In addition, nalmefene effectively reduced urges to gamble, thoughts about gambling, and the behavior itself among those subjects who received the drug compared with those who received the placebo.

Antidepressants

The serotonin (5-hydroxyindole or 5HT) system has long been associated with impulse control. Evidence for serotonergic involvement in pathological gambling comes in part from studies of platelet monoamine oxidase B (MAO-B) activity, which correlates with cerebrospinal fluid (CSF) levels of 5-hydroxyindole acetic acid (5-HIAA, a metabolite of 5-HT) and is considered a peripheral marker of 5-HT function. Low CSF 5-HIAA levels have been found to correlate with high levels of impulsiveness and sensation- seeking behaviors. As compared with control subjects, pathological gamblers show diminished activation of the ventral medial prefrontal cortex (vmPFC) when watching gambling-related videotapes or performing the Stroop color-word interference task. Pathological gamblers also show relatively diminished activation of the vmPFC during a simulated gambling task; also, the severity of their gambling problem correlated inversely with the signal intensity within this region of the brain. Together, the findings suggest that decreased serotonin function within the vmPFC may engender disinhibition and contribute to pathological gambling. Thus, drugs targeting serotonin neurotransmission have been studied as a potential treatment of pathological gambling.

Data from double-blind randomized pharmacotherapy trials of SRIs, although promising, have been inconclusive. In a double-blind placebo-controlled study using sertraline, 60 subjects who were pathological gamblers were treated for 6 months (mean dose: 95mg/d). Sertraline did not prove to be superior to placebo. At the end of the study, 23 sertraline-treated subjects (74%) and 21 placebo-treated subjects (72%) were rated as responders based on the primary outcome measure, which assessed urges to gamble and gambling behavior.

Only two SRIs have been examined in at least two randomized, placebo-controlled trials for the treatment of pathological gambling. A double-blind, 16-week crossover study of fluvoxamine in 15 pathological gamblers showed a statistically significant difference compared with placebo in reducing urges to gamble. Interpretation of the study is complicated, however, by a phase-order treatment interaction (ie, the medication did not separate from the placebo during the first phase but did in the second phase). A 6-month double-blind placebo-controlled trial of fluvoxamine in 32 gamblers failed to show statistical significance compared with placebo. The result of the latter study, however, is complicated by the fact that only 3 subjects on the medication completed the study and that the investigators saw a high placebo response rate (59%).

As with fluvoxamine, studies have failed to demonstrate consistently the efficacy of paroxetine in treating pathological gambling. An initial double-blind, placebo-controlled study of paroxetine (average end-of-study dose: 52 mg/d) showed its potential efficacy as a treatment. Significant improvement was seen in subjects randomized to 8 weeks of treatment with the drug compared with those assigned to placebo. However, researchers failed to reproduce those results in a larger, 16-week multi-center double-blind placebo-controlled trial. At the end of the study, 48% of those assigned to placebo and 59% of those taking paroxetine were considered responders.

Several important findings emerge from these antidepressant studies. First, antidepressants, particularly those that influence serotonergic systems such as serotonergic reuptake inhibitors and possibly 5-HT1/5-HT2 receptor antagonists, may be effective in reducing the symptoms of pathological gambling. Second, as in the treatment of obsessive-compulsive disorder, the doses of antidepressants required to treat pathological gambling symptoms appear to be higher than those generally required to treat depressive disorders. Third, in studies in which participants had no or minimal symptoms of depression or anxiety, antidepressants were still effective in reducing gambling symptoms. The findings suggest that these drugs may target the serotonergic systems implicated in impaired impulse regulation. Response to antidepressants usually means fewer thoughts about gambling, less participation in the behavior, and improved social and occupational functioning. Patients may initially report feeling less preoccupied with gambling and less anxious about having thoughts of gambling.

Is There A Drug To Stop Gambling

Mood Stabilizers

In one study of fluvoxamine, two out of three nonresponders saw their condition worsen with drug treatment and were observed to have symptoms of cyclothymia. These findings suggested that alternate classes of drugs, such as mood stabilizers, might be helpful for some pathological gamblers. There has been only one randomized, placebo-controlled trial of a mood stabilizer tested in pathological gamblers. In a double-blind, placebo-controlled study of 40 pathological gamblers with bipolar spectrum disorders (bipolar type II, bipolar not otherwise specified, or cyclothymia), sustained-release lithium carbonate (mean lithium level: 0.87 meq/L) was shown to be superior to placebo in reducing gambling symptoms during 10 weeks of treatment. Those taking lithium reported statistically significant improvement in terms of having thought about gambling or having the urge to gamble. No difference was found, however, in the amount of money they lost, episodes of gambling per week, or time spent per gambling episode.

Clinical Approach to Pathological Gambling

The first and most important step in treating any disorder is to diagnose it properly. Many people are ashamed of the behaviors associated with pathological gambling and, therefore, may not report that they have a problem. For that reason, clinicians need to screen for pathological gambling if the disorder is to be treated properly. A diagnostic and treatment approach is presented in Table 2.

Table 2

Screen all patients for pathological gambling. For those who screen positive, perform the following diagnostic assessment.
  1. If the person is reporting urges or cravings to gamble, consider a trial of an opioid antagonist.

  2. If the person is having a co-occurring substance use disorder, consider a trial of an opioid antagonist.

  3. If the person gambles because of depression or anxiety, or has co-occurring depressive or anxiety symptoms, consider an SRI trial.

  4. If the person gambles when hypomanic or manic or has symptoms of subsyndromal (hypo)mania, consider a trial of lithium.

  5. Always consider cognitive-behavioral therapy alone or in addition to medication.

Although pathological gambling has some shared characteristics with OCD, it also has important differences, and those differences may necessitate different treatment strategies. Many pathological gamblers also have substance abuse problems that may influence and interfere with the treatment of pathological gambling. Such conditions need to be addressed as well.

Subtyping pathological gambling based on clinical similarities to other disorders (eg, substance abuse), existence of co-occurring conditions (eg, bipolar disorder), or features of the behavior (eg, cravings), may be useful in deciding treatment interventions. Although subtyping of pathological gambling needs more research, early studies suggest that looking beyond the Diagnostic and Statistical Manual diagnostic criteria and examining what maintains the behavior may be helpful.

Although both pharmacological and psychosocial interventions have shown early promise for treating pathological gambling, no comparative studies have been done. Should treatment start with medication or therapy or both? Are there differences in individuals that may indicate a particular intervention might work better than others? More research needs to be done on such issues.

Given the pleasure associated with pathological gambling, motivating individuals to enter and adhere to treatment is difficult. High rates of treatment discontinuation (40% to 66%) are consistently seen among pathological gamblers. Rates of adherence to either psychosocial treatments or medication interventions are no better.

Conclusion

Pathological gambling has received little attention from clinicians and researchers. Despite prevalence rates similar to or greater than those for schizophrenia and bipolar disorder, much less research has been done on treatment strategies for this disorder. As a consequence, our understanding of efficacious and well-tolerated pharmacotherapies for pathological gambling lags significantly behind our understanding of treatment for other major neuropsychiatric disorders. Emerging data from controlled clinical trials, however, suggest that pathological gamblers frequently respond to pharmacological intervention.

Approaches reviewed in this article represent significant advances compared with what was available several years ago. It is hoped that progress in the treatment of pathological gambling will continue to be made at the same rate. Completion of additional, large-scale controlled studies of treatments for these disorders and comparative investigations of pharmacological agents are needed in order for physicians to offer more definitive treatment recommendations. Advances in these areas hold the potential for significantly improving the lives of pathological gamblers as well as those who are affected by their condition.

References

1. Shaffer HJ, Hall MN, Vander Bilt J. Estimating the prevalence of disordered gambling behavior in the United States and Canada: A research synthesis. Am J Public Health. 1999;89 (9):1369–76.[PMC free article] [PubMed] [Google Scholar]
2. Grant JE, Kim SW. Demographic and clinical features of 131 adult pathological gamblers. J Clin Psychiatry. 2001;62(12):957–62. [PubMed] [Google Scholar]
3. Volberg RA. The prevalence and demographics of pathological gamblers: implications for public health. Am J Pub Health. 1994;84(2):237–40.[PMC free article] [PubMed] [Google Scholar]
4. Pietrzak RH, Ladd GT, Petry NM. Disordered gambling in adolescents: epidemiology, diagnosis, and treatment. Paediatr Drugs. 2003;5(9):583–95. [PubMed] [Google Scholar]
5. Cunningham-Williams R, Cottler LB. The epidemiology of pathological gambling. Semin Clin Neuropsych. 2001;6(3):155–66. [PubMed] [Google Scholar]
6. Grant JE, Levine L, Kim D, Potenza MN. Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry. 2005;162(1):2184–8. [PubMed] [Google Scholar]
7. Stinchfield R, Govoni R, Frisch GR. Pathological gambling: a clinical guide to treatment. Washington, D.C.: American Psychiatric Publishing Inc.; 2004. Screening and assessment instruments; pp. 207–31. [Google Scholar]
8. Potenza MN, Fiellin DA, Heninger GR, Rounsaville BJ, Mazure CM. Gambling: an addictive behavior with health and primary care implications. J Gen Intern Med. 2002;17(9):721–32.[PMC free article] [PubMed] [Google Scholar]
9. Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry. 2003;160(6):1041–52.[PMC free article] [PubMed] [Google Scholar]
10. Potenza MN, Steinberg MA, McLaughlin SD, Wu R, Rounsaville BJ, O’Malley SS. Gender-related differences in the characteristics of problem gamblers using a gambling helpline. Am J Psychiatry. 2001;158(9):1500–5. [PubMed] [Google Scholar]
11. Slutske WS, Eisen S, True WR, Lyons MJ, Goldberg J, Tsuang M. Common genetic vulnerability for pathological gambling and alcohol dependence in men. Arch Gen Psychiatry. 2000;57(7):666–74. [PubMed] [Google Scholar]
12. Potenza MN, Steinberg MA, Skudlarski P, et al. Gambling urges in pathological gamblers: a functional magnetic resonance imaging study. Arch Gen Psychiatry. 2003;60(8):828–36. [PubMed] [Google Scholar]
13. Grant JE, Potenza MN. Compulsive aspects of impulse control disorders. Psychiatr Clin North Am. 2006;2(29):539–51.[PMC free article] [PubMed] [Google Scholar]
14. Adcock RA, Thangavel A, Whitfield-Gabrieli S, Knutson B, Gabrieli JD. Reward-motivated learning: mesolimbic activation prededes memory formation. Neuron. 2006;50(3):507–17. [PubMed] [Google Scholar]
15. Potenza MN, Leung HC, Blumberg HP, et al. An fMRI Stroop study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry. 2003;160(11):1990–4. [PubMed] [Google Scholar]
16. Kim SW. Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry. 1998;59(4):159–62. [PubMed] [Google Scholar]
17. Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol. 2001;16(5):285–9. [PubMed] [Google Scholar]
18. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49(11):914–21. [PubMed] [Google Scholar]
19. Kim SW, Grant JE, Adson DE, Remmel RP. A preliminary report on possible naltrexone and nonsteroidal analgesic interactions. J Clin Psychopharmacol. 2001;21(6):632–4. [letter] [PubMed] [Google Scholar]
20. Grant JE, Potenza MN, Hollander E, et al. A multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163 (12):303–12. [PubMed] [Google Scholar]

Stop Gambling Addiction

21. Grant JE, Potenza MN. Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry. 2004;16(1):27–34. [PubMed] [Google Scholar]
22. Reuter J, Raedler T, Rose M, Hand I, Glascher J, Buchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nature Neurosci. 2005;8(2):147–8. [PubMed] [Google Scholar]
23. Saiz-Ruiz J, Blanco C, Ibanez A, Masramon X, Gomez MM, Madrigal M, Diez T. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry. 2005;66(1):28–33. [PubMed] [Google Scholar]

Is There A Drug To Stop Gambling Laws

24. Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biol Psychiatry. 2000;47(9):813–7. [PubMed] [Google Scholar]
25. Blanco C, Petkova E, Ibanez A, Saiz-Ruiz J. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14(1):9–15. [PubMed] [Google Scholar]
26. Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli RM. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002;63(6):501–7. [PubMed] [Google Scholar]
27. Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-center randomized controlled trial. Int Clin Psychopharmacol. 2003;18(4):243–9. [PubMed] [Google Scholar]

Is There A Drug To Stop Gambling

28. Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162(1):137–45. [PubMed] [Google Scholar]